The Foundation for Innovative New Diagnostics (FIND) is leading a consortium, of which Mologic is part, announced today the launch of a new schistosomiasis programme within its neglected tropical diseases (NTD) portfolio.
The programme focuses on developing rapid diagnostic tests (RDTs) for detection of circulating anodic antigen (CAA) in blood and/or urine, to support national control and/or elimination programmes in countries where schistosomiasis is regularly found.
Read more on the official website: www.finddx.org/news/find-extends-neglected-tropical-diseases-portfolio-to-include-schistosomiasis/
Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care.
Our Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test. Launched in 1988, it was the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.